Stoke Therapeutics, Inc.(STOK)Earnings, Financials & Key Ratios

Key Thesis Takeaways

• Stoke Therapeutics remains a high-risk, binary-outcome biotechnology play where revenue is entirely dependent on non-recurring milestone payments rather than sustainable commercial product adoption.
• While the company maintains a high current ratio of 8.99, the underlying operational reality is defined by a $547.7 million accumulated deficit and a consistent quarterly R&D spend exceeding $20 million.
• Investors should remain cautious as the rapid exhaustion of deferred revenue, which fell from $48.4 million in 2023Q4 to $16.7 million in 2026Q1, suggests that future capital raises may be required to sustain the TANGO platform's development.